Water‐Soluble Nanoparticles with Twisted Double [7]Carbohelicene for Lysosome‐Targeted Cancer Photodynamic Therapy

• Published in: Small (Weinheim an der Bergstrasse, Germany) Vol. 18; no. 1; pp. e2105365 - n/a
• Main Authors: Zhao, Hao, Xu, Xiushang, Zhou, Long, Hu, Yunbin, Huang, Yiming, Narita, Akimitsu
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01-01-2022
• Subjects: bioimaging; Cancer; cancer treatment; carbohelicene; Cell Line, Tumor; Chemical compounds; Light irradiation; Lysosomes; Nanoparticles; Nanotechnology; Neoplasms - drug therapy; Pharmacology; Photochemotherapy; Photodynamic therapy; Photosensitizing Agents - therapeutic use; Polyethylene glycol; Singlet Oxygen; Water; White light; cancer treatment; carbohelicene; nanoparticles; photodynamic therapy; bioimaging
• ISSN: 1613-6810; 1613-6829
• DOI: 10.1002/smll.202105365

Helicene‐based therapeutic agents for organelle‐targeted photodynamic therapy (PDT) involving both type I and II are challenging and still underexplored. Herein, water‐soluble nanoparticles containing twisted double [7]carbohelicene (D7H‐NPs) are prepared through self‐assembly with 1,2‐distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐N‐[methoxy(polyethylene glycol)‐2000] by a nanoprecipitation method. D7H‐NPs display high water solubility with an average size of 46 ± 2 nm. Notably, D7H‐NPs can generate efficient singlet oxygen (1O2) and superoxide anion (O2· −) upon white light irradiation, forming the basis of PDT. Moreover, the typical accumulation in lysosomes of 4T1 cancer cells paves the way to use D7H‐NPs for lysosome‐targeted cancer phototherapeutics. This paper reports a promising helicene‐based phototherapeutic agent involving both type I and II PDT for organelle‐targeted biotherapy.
Water‐soluble nanoparticles containing twisted double [7]carbohelicene are prepared for lysosome‐targeted cancer treatment involving both type I and II photodynamic therapy (PDT). This contribution reports a promising helicene‐based phototherapeutic agent involving both type I and II PDT for organelle‐targeted biotherapy.